bullish
Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar
4.5k Views14 Mar 2025 08:30
SCD Pharma commenced bioequivalence study of oral semaglutide. Difference in technology should avoid patent dispute. The company has got commercialization partner for Eylea biosimilar in the U.S.
What is covered in the Full Insight:
- Introduction to SCD Pharma's Current Initiatives
- Oral Semaglutide Bioequivalence Study
- Global Expansion with Eylea Biosimilar
- Financial Performance and Market Impact
- Conclusion and Future Prospects
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
x